ClinicalTrials.gg
RecruitingNCT06943534OWED-TUpdated Feb 5, 2026

Omalizumab Weight-Based Dosing Efficacy Trial

A Phase 2 interventional study of 5mg/kg omalizumab injection and 15mg/kg omalizumab injection in Allergies and Food Allergy, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 1 Year to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Primary conditionFood HypersensitivityRegistry: HypersensitivityReclassifiedWhy we changed it
Registry
Hypersensitivity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Food Hypersensitivity
Why
  1. The study's listed conditions name Food Hypersensitivity, a narrower term within Hypersensitivity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
1 Year to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing omalizumab in Food Hypersensitivity — 4 open to participants now, 4 under way, none of them phase 3. Omalizumab · Food Hypersensitivity.

Planned enrollment
8th of 12
30 · median 34
Started
2025
with 1 other
Phase 2
5 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Massachusetts General Hospital

Among the 12 studies testing omalizumab in Food Hypersensitivity, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 10th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

4 of the 12 studies testing omalizumab in Food Hypersensitivity are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About omalizumab

Omalizumab: first FDA approval 2003 (XOLAIR), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.

This study: 1 Year to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing omalizumab in Food Hypersensitivity, or all of them as a file.
02

Study summary

This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.

Read the detailed description

This research is being conducted to assess the safety and effectiveness of omalizumab for food allergies dosed differently from what is currently FDA approved. The study hypothesizes the current way of dosing omalizumab may not work well for all patients with food allergy and it unnecessarily excludes some individuals with very high allergic antibody (IgE) who may benefit. This study will include subjects regardless of IgE level. One of the goals is to learn more about how safe and effective Omalizumab is for people with these high IgE levels, since this has not been fully studied before.

03

Conditions studied

  • Allergies
  • Food Allergy

Browse trials for

Keywords

  • omalizumab
04

In context

Food Hypersensitivity Reclassified

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.

Browse Food Hypersensitivity studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Food Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A positive prick skin test (PST) with a wheal ≥ 6 mm to at least two of the relevant foods (peanut, cashew, walnut, egg, or milk)
  • Positive food specific IgE (≥2.0 kUA/L) to at least two of the relevant foods
  • A positive history of clinical reaction to at least one of the qualifying foods other than the challenge-qualifying food

(If meeting above criteria):

  • Positive oral food challenge (OFC) to one of the potentially qualifying foods at a cumulative dose of ≤144 mg (maximum tolerated dose ≤30 mg)

Exclusion criteria

Exclusion Criteria:

  • Weight >80 kg at time of screening
  • laboratory abnormalities at screening.
  • Sensitivity or suspected/known allergy to any ingredients (including ) of omalizumab.
  • Poorly controlled or severe asthma/wheezing at screening
  • History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise, PICU admission f for continuous epinephrine for hypotension or severe respiratory compromise requiring intubation.
  • Treatment with a burst of oral, intramuscular (IM), or intravenous (IV) of more than two days for an indication other than asthma/wheezing within 30 days of screening.
  • Currently receiving oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers.
  • Past or current history of eosinophilic gastrointestinal disease within three years of screening.
  • Past or current history of cancer, or currently being investigated for possible cancer.
  • Past or current history of any food immunotherapy (e.g., OIT, SLIT, EPIT) within 6 months of screening.
  • Treatment with monoclonal antibody therapy, or other immunomodulatory therapy within 6 months of screening.
  • Inability to discontinue antihistamines for minimum required for SPTs or OFCs.
  • Pregnant or breastfeeding or intending to become pregnant during the study.
  • Evidence of clinically significant chronic disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Patients Receiving 5mg/kg of omalizumab

    Participants randomized to this arm will receive a does of 5mg/kg Omalizumab per month divided every two (2) weeks for 16 weeks.

    Drug: 5mg/kg omalizumab injection

  • Active comparator
    Patients Receiving 15mg/kg of omalizumab

    Participants randomized to this arm will receive a does of 15mg/kg Omalizumab per month divided every two (2) weeks for 16 weeks.

    Drug: 15mg/kg omalizumab injection

Interventions

07

What researchers measure

Primary outcomes

  1. Proportion of participants that tolerate the 600 mg dose after treatment.

    The primary analysis of outcome is on the proportion of subjects tolerating at least 600 mg at the post-treatment OFC in either group against the expected outcome without treatment based on OUTMATCH data.

    Time frame: 16 Weeks

Secondary outcomes

  1. Other measures of omalizumab treatment effect on food allergy

    Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● The proportion of participants that tolerate a single dose 1000 mg allergen

    Time frame: 16 Weeks

  2. Other measures of omalizumab treatment effect on food allergy

    Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● The proportion of participants that tolerate a single dose 2000 mg allergen

    Time frame: 16 Weeks

  3. Other measures of omalizumab treatment effect on food allergy

    Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● The proportion of participants that tolerate two doses of 2000 mg allergen

    Time frame: 16 Weeks

  4. Other measures of omalizumab treatment effect on food allergy

    Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● Reaction severity of positive post treatment reactions using the CoFAR grading scale ranging from 1 (mild) to 5 (death)

    Time frame: 16 Weeks

08

Study locations

3 of 3 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 21 months after the start.

Of 19 phase 2 interventional studies under Food Hypersensitivity, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 24, 2025
StartActual
Jul 3, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06943534
Responsible party
Wayne G. Shreffler, MD, PhD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Apr 24, 2025
Start date
Jul 3, 2025
Primary completion
May 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Feb 5, 2026

Study contacts

Jannat Gill
Contact
Jgill@mgh.harvard.edu
617-643-8683
Wayne Shreffler, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omalizumab

Start the discussion